About Crescent Biopharma Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.crescentbiopharma.com/
Frequently Asked Questions
What is the 52-week range for CBIO?
The 52-week high is $27.41 and the 52-week low is $8.72.
What is the P/E ratio for CBIO?
The P/E ratio data is currently unavailable.
What is the dividend yield for CBIO?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -100.26%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -990.32%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.81.
Analyst Recommendation Trends
Wall Street analyst consensus for CBIO over the last few months:
Latest CBIO News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 26.8% to $0.32 during Tuesday's pre-market session. The company's market cap stands at $1.3 million. Summit Therapeutics (NASDAQ:SMMT) stock rose 16.34%
Crescent Biopharma Announces Grants of Inducement Awards
WALTHAM, Mass., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 31,200 shares of the Company’s ordinary shares to two non-executive employees as equity inducement awards under the
The Nascent Crescent Biopharma Thesis: One Year Later And Things Are Steady
Crescent Biopharma (CBIO) stays a Buy: CR-001 Phase 1/2 data due Q1 2027, $305M cash runway to H2 2028, PD-1/VEGF upsideâread now.
Crescent Biopharma, Inc. (CBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Crescent Biopharma, Inc. (CBIO) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 5:35 PM EDTCompany ParticipantsJoshua Brumm - CEO...
Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Target
Wedbush analyst Robert Driscoll reiterates Crescent Biopharma (NASDAQ:CBIO) with a Outperform and maintains $27 price target.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-18 | Brumm Joshua T | -7,837 | $16.71 | $130,956 |
| 2026-09-18 | McNeill Jonathan | -3,839 | $16.71 | $64,150 |
| 2026-09-16 | Lynch Ryan | -240 | $17.9 | $4,296 |
| 2026-09-16 | Pinkas Jan | -658 | $17.9 | $11,778 |
| 2026-09-16 | Im Ellie Eunkyung | -623 | $17.9 | $11,152 |
| 2026-09-16 | Scalzo Richard William | -568 | $17.9 | $10,167 |
| 2026-09-16 | Bispham Barbara Harlin | -620 | $17.9 | $11,098 |
| 2026-09-16 | Brumm Joshua T | -1,610 | $17.9 | $28,819 |
| 2026-09-16 | McNeill Jonathan | -731 | $17.9 | $13,085 |
| 2026-07-16 | Fairmount Funds Management LLC | +525,897 | $14.499 | $7,624,981 |
| 2026-07-16 | Fairmount Funds Management LLC | +853,450 | $14.5 | $12,375,025 |
| 2026-06-22 | Lynch Ryan | -465 | $17.99 | $8,365 |
| 2026-06-22 | Pinkas Jan | -1,288 | $17.99 | $23,171 |
| 2026-06-22 | Scalzo Richard William | -1,112 | $17.99 | $20,005 |
| 2026-06-22 | Bispham Barbara Harlin | -1,218 | $17.99 | $21,912 |
| 2026-06-22 | Im Ellie Eunkyung | -1,219 | $17.99 | $21,930 |
| 2026-06-22 | McNeill Jonathan | -20,549 | $17.99 | $369,677 |
| 2026-06-22 | Brumm Joshua T | -42,305 | $17.99 | $761,067 |
| 2026-06-02 | Violin Jonathan | +11,050 | - | - |
| 2026-06-02 | Lubner David Charles | +11,050 | - | - |
| 2026-06-02 | Balcom Alexandra | +11,050 | - | - |
| 2026-06-02 | Moran Susan | +11,050 | - | - |
| 2026-06-02 | Fairmount Healthcare Fund II L.P. | +11,050 | - | - |
| 2025-12-15 | Pinkas Jan | +70,025 | - | - |
| 2025-12-15 | Pinkas Jan | +5,000 | - | - |
| 2025-12-15 | Pinkas Jan | +17,507 | - | - |
| 2025-12-15 | Doughty Christopher Grant | +58,855 | - | - |
| 2025-12-15 | Doughty Christopher Grant | +8,000 | - | - |
| 2025-12-15 | Doughty Christopher Grant | +14,714 | - | - |
| 2025-12-15 | Brumm Joshua T | +180,467 | - | - |
| 2025-12-15 | Brumm Joshua T | +10,000 | - | - |
| 2025-12-15 | Brumm Joshua T | +45,117 | - | - |
| 2025-12-15 | Scalzo Richard William | +57,688 | - | - |
| 2025-12-15 | Scalzo Richard William | +5,000 | - | - |
| 2025-12-15 | Scalzo Richard William | +14,422 | - | - |
| 2025-12-15 | McNeill Jonathan | +78,029 | - | - |
| 2025-12-15 | McNeill Jonathan | +6,000 | - | - |
| 2025-12-15 | McNeill Jonathan | +19,507 | - | - |
| 2025-12-15 | Im Ellie Eunkyung | +65,190 | - | - |
| 2025-12-15 | Im Ellie Eunkyung | +5,000 | - | - |
| 2025-12-15 | Im Ellie Eunkyung | +16,298 | - | - |
| 2025-12-15 | Lynch Ryan | +33,512 | - | - |
| 2025-12-15 | Lynch Ryan | +4,000 | - | - |
| 2025-12-15 | Lynch Ryan | +8,378 | - | - |
| 2025-12-15 | Bispham Barbara Harlin | +72,185 | - | - |
| 2025-12-15 | Bispham Barbara Harlin | +6,000 | - | - |
| 2025-12-15 | Bispham Barbara Harlin | +12,422 | - | - |
| 2025-12-08 | McNeill Jonathan | +172,836 | - | - |
| 2025-12-08 | Brumm Joshua T | +345,672 | - | - |
| 2025-12-04 | Fairmount Healthcare Fund II L.P. | +131,434 | $13.409 | $1,762,399 |
| 2025-12-04 | Fairmount Healthcare Fund II L.P. | +1,360,000 | $13.41 | $18,237,600 |